Across TCGA pan-cancer cohorts, ZNF45 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ZNF45 data layer compared with 23 for mass-spec protein and 6 for mutation status.
The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ZNF45 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ZNF45 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.
CCRCC and OV are the cancer types where ZNF45 mass-spec protein most reproducibly stratifies survival.